Abbott Laboratories Earnings Call Insights: GAAP Numbers and Key Growth Numbers

Abbott Laboratories (NYSE:ABT) recently reported its fourth quarter earnings and discussed the following topics in its earnings conference call.

GAAP Numbers

Michael Weinstein – JPMorgan: I have a bunch of questions. Let me start with, could you just spend a minute on – Tom on the spread between the GAAP and cash guidance for 2013, it’s obviously more than the amortization expense. So are you just assuming certain charges that will run through over the course of the year, and that’s why the GAAP numbers are off?

Thomas C. Freyman – EVP, Finance and CFO: Yeah, there’s two basic things happened beyond amortization. There is a little bit of post-separation, I’d call it residual separation cost and there is some previously announced actions we took in areas of cost reduction, particularly in areas that impact manufacturing that do carry over into 2013. So that’s the difference.

Michael Weinstein – JPMorgan: Then can you add – two questions. One, do you have, Tom, a new Abbott EPS number at this point for 2012? Then second, can you aggregate at all the divisional revenue guidance to which your organic revenue guidance is and reported revenue guidance for 2013 for the total Company?